Figure 2.

Frequency of selected treatment-emergent adverse effects, based on pooled data from short-term randomized trials of vortioxetine in adults with major depression.

Notes: This graph displays the pooled frequency of selected treatment-emergent adverse effects by vortioxetine dose from short-term (6–8 weeks) placebo-controlled studies in adults with major depression (2,616 were treated with vortioxetine), as reported in the vortioxetine drug label. Only selected adverse effects that occurred in ≥2% of vortioxetine-treated patients at any dose and occurred ≥2% more frequently with vortioxetine than with placebo are shown.